Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.

PURPOSE Approximately one-third of all Renal Cell Carcinoma (RCC) patients undergoing a nephrectomy face metastatic disease. The availability of novel therapeutics for metastatic patients underscores the importance of identifying patients at risk of recurrence or patients responding well to specific therapies. Unlike clear cell RCC (ccRCC), information on biomarkers for the papillary subtype (pRCC) remains limited. In this review, we identified tissue markers that are differentially expressed between subtypes and may be of diagnostic use. In addition, markers with promising prognostic power for ccRCC and/or pRCC are described and their clinical value is discussed. MATERIALS AND METHODS To identify diagnostic markers that differentiate between pRCC and ccRCC a Pubmed search was performed, limited to original articles published in the English language between 1990 and 2009, using the terms pRCC/papillary RCC/papillary renal cell carcinoma/papillary kidney cancer, biomarker/biomarkers, protein expression, mass spectrometry and immunohistochemistry. Prognostic markers for ccRCC and pRCC were identified using the search terms kidney cancer, renal cell carcinoma, prognostic marker, biomarker and prognosis. Only markers with independent prognostic value in multivariable analysis were included. RESULTS 25 proteins are differentially expressed between ccRCC and pRCC, reflecting the molecularly distinct nature of these subtypes. 5 of these proteins were externally validated, which shows their diagnostic potential. Whereas 48 biomarkers with independent prognostic power have been identified for ccRCC patients, only CD44, CA9, p53, Ki67 and PCNA have shown prognostic value in multiple studies. Expression of IMP-3 and VEGF-R2 are independent predictors of survival of pRCC patients, although this is shown in single studies. CONCLUSIONS So far 5 validated diagnostic markers are able to differentiate between ccRCC and pRCC. Few independent prognostic markers have been identified for pRCC in single studies, compared to numerous biomarkers identified for the more common ccRCC. Despite the abundance of promising markers for ccRCC, their exact role in clinical decision making still needs to be established through validation studies.

[1]  Y. Oda,et al.  Low expression of p27Kip1 is associated with tumor size and poor prognosis in patients with renal cell carcinoma , 2002 .

[2]  G. Brewer,et al.  The RNA-binding Protein IMP-3 Is a Translational Activator of Insulin-like Growth Factor II Leader-3 mRNA during Proliferation of Human K562 Leukemia Cells* , 2005, Journal of Biological Chemistry.

[3]  P. Rehak,et al.  Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. , 2004, Urology.

[4]  Alamdari,et al.  Follow‐up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy , 1999, BJU international.

[5]  S. Horvath,et al.  Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. , 2005, The Journal of urology.

[6]  A. Belldegrun,et al.  Molecular Signatures of Localized Clear Cell Renal Cell Carcinoma to Predict Disease-Free Survival after Nephrectomy , 2009, Cancer Epidemiology Biomarkers & Prevention.

[7]  S. Horvath,et al.  Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. , 2004, The Journal of urology.

[8]  Ximing J. Yang,et al.  Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma , 2004, The American journal of surgical pathology.

[9]  M. Atkins.  Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy , 2009, Medical Oncology.

[10]  M. Carini,et al.  Nuclear Expression of Hypoxia-inducible Factor-1α in Clear Cell Renal Cell Carcinoma is Involved in Tumor Progression , 2007, The American journal of surgical pathology.

[11]  K. Miller,et al.  Expression of the Apoptosis Inhibitor Livin in Renal Cell Carcinomas: Correlations with Pathology and Outcome , 2007, Tumor Biology.

[12]  K. Rock,et al.  Oncofetal protein IMP3 , 2008, Cancer.

[13]  G. Gokce,et al.  Prognostic value of the expression of Ki‐67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma , 2004, BJU international.

[14]  B. Delahunt,et al.  Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. , 2001, Human pathology.

[15]  A. Lopez‐Beltran,et al.  2009 update on the classification of renal epithelial tumors in adults , 2009, International journal of urology : official journal of the Japanese Urological Association.

[16]  C. P. Evans,et al.  Management approaches to small renal tumours , 2006, BJU international.

[17]  W. Kaelin,et al.  Role of VHL gene mutation in human cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Y. Allory,et al.  Papillary renal cell carcinoma , 2003, Virchows Archiv.

[19]  F. Autschbach,et al.  High nuclear Livin expression is a favourable prognostic indicator in renal cell carcinoma , 2008, BJU international.

[20]  R. Motzer,et al.  Renal-cell carcinoma. , 1996, The New England journal of medicine.

[21]  M. Mazumdar,et al.  Messenger RNA Expression Ratios among Four Genes Predict Subtypes of Renal Cell Carcinoma and Distinguish Oncocytoma from Carcinoma , 2005, Clinical Cancer Research.

[22]  A. Ravaud,et al.  Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Patard,et al.  A critical assessment of the prognostic value of clear cell, papillary and chromophobe histological subtypes in renal cell carcinoma: a population‐based study , 2009, BJU international.

[24]  A. Young,et al.  Current Trends in the Molecular Classification of Renal Neoplasms , 2006, TheScientificWorldJournal.

[25]  Stephanie Daignault,et al.  Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect , 2006 .

[26]  M. Jordá,et al.  Diagnostic and prognostic molecular markers in renal cell carcinoma. , 2008, The Journal of urology.

[27]  R. Figlin,et al.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Pier,et al.  Oncocytoma Can be Differentiated From its Renal Cell Carcinoma Mimics by a Panel of Markers: An Automated Tissue Microarray Study , 2009, Applied immunohistochemistry & molecular morphology : AIMM.

[29]  N. Rioux-Leclercq,et al.  Clinical significance of cell proliferation, microvessel density, and CD44 adhesion molecule expression in renal cell carcinoma. , 2001, Human pathology.

[30]  H. Aburatani,et al.  Papillary Renal Cell Carcinoma: Quantitation of Chromosomes 7 and 17 by FISH, Analysis of Chromosome 3p for LOH, and DNA Ploidy , 1996, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[31]  R. Figlin,et al.  p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. , 2007, The Journal of urology.

[32]  B Cochand-Priollet,et al.  Profiling and classification tree applied to renal epithelial tumours , 2007, Histopathology.

[33]  J. Cheville,et al.  High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma , 2006, Cancer.

[34]  C. Langner,et al.  Keratin immunohistochemistry in renal cell carcinoma subtypes and renal oncocytomas: a systematic analysis of 233 tumors , 2004, Virchows Archiv.

[35]  C. Lohse,et al.  Development and evaluation of BioScore , 2009, Cancer.

[36]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[37]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[38]  H. Moch,et al.  Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. , 2009, European urology.

[39]  M. Marberger,et al.  Expression of the cell cycle proteins p21, p27, and pRb in clear cell renal cell carcinoma and their prognostic significance. , 2001, Urology.

[40]  A. Haitel,et al.  Expression of aquaporins and PAX-2 compared to CD10 and cytokeratin 7 in renal neoplasms: a tissue microarray study , 2005, Modern Pathology.

[41]  A. Folpe,et al.  Distribution of Cytokeratins and Vimentin in Adult Renal Neoplasms and Normal Renal Tissue: Potential Utility of a Cytokeratin Antibody Panel in the Differential Diagnosis of Renal Tumors , 2005, The American journal of surgical pathology.